{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T16:45:01Z","timestamp":1786985101257,"version":"build-2736575974"},"reference-count":57,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Best Practice & Research Clinical Rheumatology"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.berh.2026.102140","type":"journal-article","created":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T20:22:19Z","timestamp":1779135739000},"page":"102140","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Chimeric antigen receptor T-cell (CAR-T) therapy and other cellular immunotherapy treatments for idiopathic inflammatory myopathies"],"prefix":"10.1016","volume":"40","author":[{"given":"Jisna R.","family":"Paul","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prateek C.","family":"Gandiga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rohit","family":"Aggarwal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9","key":"10.1016\/j.berh.2026.102140_bib1","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1038\/s41584-024-01139-z","article-title":"Advancements and challenges in CAR T cell therapy in autoimmune diseases","volume":"20","author":"Schett","year":"2024","journal-title":"Nat Rev Rheumatol"},{"issue":"22","key":"10.1016\/j.berh.2026.102140_bib2","doi-asserted-by":"crossref","first-page":"1924","DOI":"10.1001\/jama.2024.19462","article-title":"CAR T cells and T-Cell therapies for cancer: a translational science review","volume":"332","author":"Brudno","year":"2024","journal-title":"JAMA"},{"key":"10.1016\/j.berh.2026.102140_bib3","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2025.103621","article-title":"Anti-BCMA\/CD19 CAR T cell therapy in patients with refractory generalized myasthenia gravis: a single-arm, phase 1 trial","volume":"90","author":"Zhang","year":"2025","journal-title":"eClinicalMedicine"},{"key":"10.1016\/j.berh.2026.102140_bib4","unstructured":"Mougiakakos D, Kr\u00f6nke G, V\u00f6lkl S, Kretschmann S, Aigner M, Kharboutli S, B\u00f6ltz S, Manger B, Mackensen A, Schett G: CD19-Targeted CAR T cells in refractory systemic lupus erythematosus..."},{"key":"10.1016\/j.berh.2026.102140_bib5","unstructured":"Shumnalieva R, Velikova T, Monov S: Expanding the role of CAR t\u2010cell therapy: from b\u2010cell hematological malignancies to autoimmune rheumatic diseases..."},{"issue":"8","key":"10.1016\/j.berh.2026.102140_bib6","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1056\/NEJMoa2308917","article-title":"CD19 CAR T-Cell therapy in autoimmune disease - a case series with Follow-up","volume":"390","author":"M\u00fcller","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.berh.2026.102140_bib7","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/B978-0-323-98818-6.00023-6","article-title":"Autoimmune inflammatory myopathies","volume":"195","author":"Dalakas","year":"2023","journal-title":"Handb Clin Neurol"},{"issue":"8","key":"10.1016\/j.berh.2026.102140_bib8","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1002\/art.41762","article-title":"Expert perspective: management of refractory inflammatory myopathy","volume":"73","author":"Lundberg","year":"2021","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.berh.2026.102140_bib9","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2025.1581323","article-title":"Emerging B and plasma cell-targeting immune therapies in idiopathic inflammatory myopathies","volume":"16","author":"Groener","year":"2025","journal-title":"Front Immunol"},{"issue":"1","key":"10.1016\/j.berh.2026.102140_bib10","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1136\/annrheumdis-2018-213518","article-title":"Pathogenicity of IgG from patients with anti-SRP or anti-HMGCR autoantibodies in immune-mediated necrotising myopathy","volume":"78","author":"Bergua","year":"2019","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"10.1016\/j.berh.2026.102140_bib11","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1002\/art.37754","article-title":"Rituximab in the treatment of refractory adult and juvenile dermatomyositis and adult polymyositis: a randomized, placebo-phase trial","volume":"65","author":"Oddis","year":"2013","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.berh.2026.102140_bib12","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.1051609","article-title":"Efficacy and safety of rituximab treatment in patients with idiopathic inflammatory myopathies: a systematic review and meta-analysis","volume":"13","author":"Zhen","year":"2022","journal-title":"Front Immunol"},{"issue":"3","key":"10.1016\/j.berh.2026.102140_bib13","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1093\/rheumatology\/kead281","article-title":"Belimumab treatment of adult idiopathic inflammatory myopathy","volume":"63","author":"Marder","year":"2024","journal-title":"Rheumatology"},{"issue":"3","key":"10.1016\/j.berh.2026.102140_bib14","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/j.ard.2025.07.004","article-title":"Efficacy of obinutuzumab in two rituximab refractory cases of idiopathic inflammatory myopathies with severe interstitial lung disease","volume":"85","author":"St\u00fctz","year":"2025","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.berh.2026.102140_bib15","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/s41073-019-0064-8","article-title":"SANRA-a scale for the quality assessment of narrative review articles","volume":"4","author":"Baethge","year":"2019","journal-title":"Res Integr Peer Rev"},{"issue":"5","key":"10.1016\/j.berh.2026.102140_bib16","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1038\/s41584-019-0211-0","article-title":"B cell checkpoints in autoimmune rheumatic diseases","volume":"15","author":"Rubin","year":"2019","journal-title":"Nat Rev Rheumatol"},{"issue":"3","key":"10.1016\/j.berh.2026.102140_bib17","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1038\/nrrheum.2011.1","article-title":"Long-lived autoreactive plasma cells drive persistent autoimmune inflammation","volume":"7","author":"Hiepe","year":"2011","journal-title":"Nat Rev Rheumatol"},{"issue":"9","key":"10.1016\/j.berh.2026.102140_bib18","doi-asserted-by":"crossref","first-page":"1710","DOI":"10.1093\/rheumatology\/kew275","article-title":"Autoantibody levels in myositis patients correlate with clinical response during B cell depletion with rituximab","volume":"55","author":"Aggarwal","year":"2016","journal-title":"Rheumatology"},{"issue":"11","key":"10.1016\/j.berh.2026.102140_bib19","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1136\/ard-2024-225773","article-title":"Pathological autoantibody internalisation in myositis","volume":"83","author":"Pinal-Fernandez","year":"2024","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.1016\/j.berh.2026.102140_bib20","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1038\/s41392-024-01998-8","article-title":"Allogeneic CAR T cells for autoimmune diseases: a glimpse into the future","volume":"9","author":"Mougiakakos","year":"2024","journal-title":"Signal Transduct Target Ther"},{"issue":"3","key":"10.1016\/j.berh.2026.102140_bib21","doi-asserted-by":"crossref","DOI":"10.1016\/j.beha.2024.101566","article-title":"Allogeneic \"Off-the-Shelf\" CAR T cells: challenges and advances","volume":"37","author":"Chen","year":"2024","journal-title":"Best Pract Res Clin Haematol"},{"issue":"1","key":"10.1016\/j.berh.2026.102140_bib22","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.tips.2025.11.001","article-title":"Autologous, allogeneic, in vivo CAR for autoimmune diseases","volume":"47","author":"Li","year":"2026","journal-title":"Trends Pharmacol Sci"},{"issue":"6","key":"10.1016\/j.berh.2026.102140_bib23","doi-asserted-by":"crossref","first-page":"e434","DOI":"10.1016\/S2665-9913(24)00377-1","article-title":"CAR T-cell therapy in autoimmune diseases: where are we and where are we going?","volume":"7","author":"Scherlinger","year":"2025","journal-title":"Lancet Rheumatol"},{"key":"10.1016\/j.berh.2026.102140_bib24","doi-asserted-by":"crossref","DOI":"10.1177\/1756286418761697","article-title":"B cell-based therapies in CNS autoimmunity: differentiating CD19 and CD20 as therapeutic targets","volume":"11","author":"Forsthuber","year":"2018","journal-title":"Ther Adv Neurol Disord"},{"issue":"5","key":"10.1016\/j.berh.2026.102140_bib25","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1007\/s40291-024-00730-0","article-title":"The future of CAR T therapeutics to treat autoimmune disorders","volume":"28","author":"Pecher","year":"2024","journal-title":"Mol Diagn Ther"},{"key":"10.1016\/j.berh.2026.102140_bib26","unstructured":"Aggarwal A, Almackenzie M, Aggarwal R: Role of CD19 chimeric antigen receptor T cell therapy in idiopathic inflammatory myopathies..."},{"key":"10.1016\/j.berh.2026.102140_bib27","article-title":"CARing about autoimmune disorders. Use of chimeric antigen receptor engineered T-cells in autoimmune diseases","author":"Tigu","year":"2025","journal-title":"Blood Rev"},{"issue":"1","key":"10.1016\/j.berh.2026.102140_bib28","doi-asserted-by":"crossref","first-page":"e12","DOI":"10.1093\/rheumatology\/kead330","article-title":"Rescue therapy of antisynthetase syndrome with CD19-targeted CAR-T cells after failure of several B-cell depleting antibodies","volume":"63","author":"Taubmann","year":"2024","journal-title":"Rheumatology"},{"issue":"24","key":"10.1016\/j.berh.2026.102140_bib29","doi-asserted-by":"crossref","first-page":"2154","DOI":"10.1001\/jama.2023.8753","article-title":"CD19-Targeting CAR T cells for myositis and interstitial lung disease associated with antisynthetase syndrome","volume":"329","author":"Pecher","year":"2023","journal-title":"JAMA"},{"issue":"10379","key":"10.1016\/j.berh.2026.102140_bib30","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1016\/S0140-6736(23)00023-5","article-title":"CD19-targeted CAR T cells in refractory antisynthetase syndrome","volume":"401","author":"M\u00fcller","year":"2023","journal-title":"Lancet"},{"issue":"9","key":"10.1016\/j.berh.2026.102140_bib31","doi-asserted-by":"crossref","first-page":"5101","DOI":"10.1093\/rheumatology\/keaf190","article-title":"A novel approach to refractory idiopathic inflammatory myopathy: CD19 CAR T-cell therapy-case report and literature review","volume":"64","author":"Haase","year":"2025","journal-title":"Rheumatology"},{"issue":"6","key":"10.1016\/j.berh.2026.102140_bib32","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1038\/s41591-025-03718-3","article-title":"BCMA CAR T cells in a patient with relapsing idiopathic inflammatory myositis after initial and repeat therapy with CD19 CAR T cells","volume":"31","author":"M\u00fcller","year":"2025","journal-title":"Nat Med"},{"issue":"suppl 9","key":"10.1016\/j.berh.2026.102140_bib33","article-title":"RESET-Myositis: clinical trial evaluating rese-cel (resecabtagene Autoleucel), A fully human, autologous 4-1BB CD19-CAR T cell therapy in idiopathic inflammatory myopathies [abstract]","volume":"77","author":"Wilfong","year":"2025","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.berh.2026.102140_bib34","series-title":"ACR convergence: 2025; Chicago","article-title":"Data and results update presentations for RESET-Myositis (RESET-IIM) (conference presentation PDFs\/slides)","year":"2025"},{"issue":"suppl 9","key":"10.1016\/j.berh.2026.102140_bib35","article-title":"Promising early outcomes with BMS-986353, a CD19-directed chimeric antigen receptor T cell therapy in severe refractory idiopathic inflammatory myopathies: safety and efficacy findings from the ongoing phase 1 tria. In: ACR convergence 2025","volume":"77","author":"Aggarwal","year":"2025","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.berh.2026.102140_bib36","unstructured":"Shepherd C, Chinoy H: RESET-Myositis: an open-label Study to evaluate the safety and efficacy of CABA-201 in subjects with active idiopathic inflammatory myopathy..."},{"issue":"11","key":"10.1016\/j.berh.2026.102140_bib37","doi-asserted-by":"crossref","first-page":"3821","DOI":"10.1016\/j.ymthe.2024.09.009","article-title":"Case study of CD19 CAR T therapy in a subject with immune-mediate necrotizing myopathy treated in the RESET-Myositis phase I\/II trial","volume":"32","author":"Volkov","year":"2024","journal-title":"Mol Ther"},{"issue":"6","key":"10.1016\/j.berh.2026.102140_bib38","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2315990121","article-title":"Single-cell analysis of refractory anti-SRP necrotizing myopathy treated with anti-BCMA CAR-T cell therapy","volume":"121","author":"Qin","year":"2024","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"10","key":"10.1016\/j.berh.2026.102140_bib39","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1002\/art.42933","article-title":"Autologous CD19-Targeting CAR T cells in a patient with refractory juvenile dermatomyositis","volume":"76","author":"Nicolai","year":"2024","journal-title":"Arthritis Rheumatol"},{"issue":"8","key":"10.1016\/j.berh.2026.102140_bib40","doi-asserted-by":"crossref","DOI":"10.1016\/j.medj.2025.100676","article-title":"CD19 CAR-T cell therapy in a pediatric patient with MDA5","volume":"6","author":"Par\u00eds-Mu\u00f1oz","year":"2025","journal-title":"Med"},{"key":"10.1016\/j.berh.2026.102140_bib41","doi-asserted-by":"crossref","DOI":"10.1038\/s41591-025-04185-6","article-title":"CD19 CAR-T cells for treatment-refractory autoimmune diseases: the phase 1\/2 CASTLE basket trial","author":"M\u00fcller","year":"2026","journal-title":"Nat Med"},{"issue":"11","key":"10.1016\/j.berh.2026.102140_bib42","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1038\/s41577-024-01035-3","article-title":"Chimeric antigen receptor T cell therapy for autoimmune disease","volume":"24","author":"Chung","year":"2024","journal-title":"Nat Rev Immunol"},{"issue":"6","key":"10.1016\/j.berh.2026.102140_bib43","doi-asserted-by":"crossref","first-page":"532","DOI":"10.3899\/jrheum.2024-1115","article-title":"Role of CD19 chimeric antigen receptor T cell therapy in idiopathic inflammatory myopathies","volume":"52","author":"Aggarwal","year":"2025","journal-title":"J Rheumatol"},{"issue":"6","key":"10.1016\/j.berh.2026.102140_bib44","doi-asserted-by":"crossref","first-page":"e424","DOI":"10.1016\/S2665-9913(25)00091-8","article-title":"Local immune effector cell-associated toxicity syndrome in CAR T-cell treated patients with autoimmune disease: an observational study","volume":"7","author":"Hagen","year":"2025","journal-title":"Lancet Rheumatol"},{"issue":"2","key":"10.1016\/j.berh.2026.102140_bib45","doi-asserted-by":"crossref","DOI":"10.3390\/ijms26020467","article-title":"Exploring CAR T-Cell dynamics: balancing potent cytotoxicity and controlled inflammation in CAR T-Cells derived from systemic sclerosis and Myositis patients","volume":"26","author":"Dingfelder","year":"2025","journal-title":"Int J Mol Sci"},{"issue":"1","key":"10.1016\/j.berh.2026.102140_bib46","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1186\/s40164-025-00633-8","article-title":"The clinical landscape of CAR NK cells","volume":"14","author":"J\u00f8rgensen","year":"2025","journal-title":"Exp Hematol Oncol"},{"issue":"suppl 9","key":"10.1016\/j.berh.2026.102140_bib47","first-page":"2025","article-title":"NKX019, an allogeneic off-the-shelf CD19 targeting CAR-NK cell therapy, induces deep CD19+ B cell depletion in hematological malignancy and models of autoimmune disease in: ACR convergence","volume":"77","author":"Tohm\u00e9","year":"2025","journal-title":"Chicago: Arthritis Rheumatol"},{"key":"10.1016\/j.berh.2026.102140_bib48","article-title":"CAR-based cell therapy for autoimmune diseases","volume":"16","author":"Li","year":"2025","journal-title":"Front Immunol"},{"issue":"11","key":"10.1016\/j.berh.2026.102140_bib49","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1016\/j.ard.2025.07.028","article-title":"Genetically modified CD19-targeting IL-15 secreting NK cells for the treatment of systemic lupus erythematosus","volume":"84","author":"Fu","year":"2025","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.berh.2026.102140_bib50","article-title":"Chimeric antigen receptor T-cell therapy in autoimmune diseases","volume":"15","author":"Liu","year":"2024","journal-title":"Front Immunol"},{"issue":"9","key":"10.1016\/j.berh.2026.102140_bib51","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1056\/NEJMoa1609783","article-title":"Blinatumomab versus chemotherapy for advanced acute lymphoblastic leukemia","volume":"376","author":"Kantarjian","year":"2017","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.berh.2026.102140_bib52","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2025-013285","article-title":"Advancing adoptive T cell therapy in ovarian cancer: barriers, innovations, and emerging platforms","volume":"14","author":"Santos","year":"2026","journal-title":"J Immunother Cancer"},{"issue":"6","key":"10.1016\/j.berh.2026.102140_bib53","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1038\/s41591-024-02964-1","article-title":"Bispecific T cell engager therapy for refractory rheumatoid arthritis","volume":"30","author":"Bucci","year":"2024","journal-title":"Nat Med"},{"issue":"11","key":"10.1016\/j.berh.2026.102140_bib54","doi-asserted-by":"crossref","DOI":"10.1002\/ctm2.70046","article-title":"Natural killer cell engagers: from bi-specific to tri-specific and tetra-specific engagers for enhanced cancer immunotherapy","volume":"14","author":"Zhu","year":"2024","journal-title":"Clin Transl Med"},{"key":"10.1016\/j.berh.2026.102140_bib55","article-title":"Current strategies for armoring chimeric antigen receptor T-cells to overcome barriers of the solid tumor microenvironment","volume":"16","author":"Yang","year":"2025","journal-title":"Front Immunol"},{"issue":"4","key":"10.1016\/j.berh.2026.102140_bib56","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1002\/art.43038","article-title":"Clinical characteristics of anti-synthetase syndrome: analysis from the classification criteria for anti-synthetase syndrome Project","volume":"77","author":"Faghihi-Kashani","year":"2025","journal-title":"Arthritis Rheumatol"},{"issue":"7","key":"10.1016\/j.berh.2026.102140_bib57","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1136\/ard-2023-224652","article-title":"Current myositis clinical trials and tribulations","volume":"83","author":"Saygin","year":"2024","journal-title":"Ann Rheum Dis"}],"container-title":["Best Practice & Research Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521694226000252?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521694226000252?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T07:46:25Z","timestamp":1781509585000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521694226000252"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":57,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["S1521694226000252"],"URL":"https:\/\/doi.org\/10.1016\/j.berh.2026.102140","relation":{},"ISSN":["1521-6942"],"issn-type":[{"value":"1521-6942","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Chimeric antigen receptor T-cell (CAR-T) therapy and other cellular immunotherapy treatments for idiopathic inflammatory myopathies","name":"articletitle","label":"Article Title"},{"value":"Best Practice & Research Clinical Rheumatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.berh.2026.102140","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"102140"}}